SPOBAG AG Net Assets
SPOBAG AG net assets. Based on the latest financial reports, SPOBAG AG (SBE) has net assets worth €0.00 EUR (≈ $0.00 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€339.85K ≈ $397.32K USD) and total liabilities (€339.85K ≈ $397.32K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of SPOBAG AG to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €0.00 |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of SPOBAG AG (2016–2024)
Net assets of SPOBAG AG from 2016 to 2024. This chart illustrates how SPOBAG AG's net assets have evolved over time, based on quarterly financial data. See SBE equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for SPOBAG AG (2016–2024)
The table below shows the annual net assets of SPOBAG AG from 2016 to 2024. For live market cap and overall valuation, see SBE company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €0.00 ≈ $0.00 |
-- |
| 2023-12-31 | €0.00 ≈ $0.00 |
-- |
| 2022-12-31 | €0.00 ≈ $0.00 |
-- |
| 2021-12-31 | €0.00 ≈ $0.00 |
-- |
| 2020-12-31 | €0.00 ≈ $0.00 |
-- |
| 2019-12-31 | €-116.66K ≈ $-136.38K |
-58.74% |
| 2018-12-31 | €-73.49K ≈ $-85.92K |
-187.61% |
| 2017-12-31 | €-25.55K ≈ $-29.87K |
-193.23% |
| 2016-12-31 | €27.41K ≈ $32.04K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SPOBAG AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 59906010.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SPOBAG AG Net Assets Breakdown (December 2024)
SPOBAG AG net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.62 Million | % |
| Total Equity | €0.00 | 100.00% |
SPOBAG AG Competitors by Market Cap
The table below lists competitors of SPOBAG AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MOJ S.A
WAR:MOJ
|
$3.92 Million |
|
Adamera Minerals Corp.
V:ADZ
|
$3.92 Million |
|
Vnsteel Vicasa JSC
VN:VCA
|
$3.92 Million |
|
EURO MANGANESE CDI/1
F:E06A
|
$3.93 Million |
|
Tarrina Resources Limited
AU:TR8
|
$3.92 Million |
|
Americore Resources Corp.
V:AMCO
|
$3.92 Million |
|
Bank Mayapada Internasional
JK:MAYA
|
$3.91 Million |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
$3.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SPOBAG AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 0 to 0, a change of 0.
- Net loss of 149,158 reduced equity.
- Other factors increased equity by 149,158.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-149.16K | -0.0% |
| Other Changes | €149.16K | +0.0% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares SPOBAG AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-0.05 | €20.00 | x |
| 2018-12-31 | €-0.15 | €20.00 | x |
| 2019-12-31 | €-0.23 | €20.00 | x |
| 2020-12-31 | €0.00 | €20.00 | x |
| 2021-12-31 | €0.00 | €20.00 | x |
| 2022-12-31 | €0.00 | €20.00 | x |
| 2023-12-31 | €0.00 | €20.00 | x |
| 2024-12-31 | €0.00 | €20.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SPOBAG AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-67.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -608.52% | 0.00% | 0.00x | 2.88x | €-169.53K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | €-50.41K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | €-40.59K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | €-31.50K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | €-63.79K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-48.28K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-71.56K |
| 2023 | 0.00% | -1427.28% | 0.09x | 0.00x | €-122.19K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-149.16K |
Industry Comparison
This section compares SPOBAG AG's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SPOBAG AG (SBE) | €0.00 | -608.52% | N/A | $3.92 Million |
| Covestro AG (1COV) | $5.64 Billion | 8.13% | 1.29x | $11.10 Billion |
| CENTESSA PHARMACEUTICALS (260) | $336.17 Million | -64.31% | 0.32x | $5.35 Billion |
| 2invest AG (2INV) | $63.16 Million | 2.50% | 0.02x | $70.69 Million |
| COINSHARES I. LS-000247 (3TW) | $-1.41K | 0.00% | 0.00x | $472.53 Million |
| Adaptimmune Therapeutics plc (473A) | $81.88 Million | -202.08% | 3.02x | $42.94 Million |
| KINGMAN MINERALS LTD. (47A) | $1.44 Million | -21.74% | 0.28x | $81.08K |
| GENOR BIOPHARMA DL-00002 (67N0) | $1.81 Billion | -40.45% | 0.17x | $93.97 Million |
| BENO Holding AG (BENH) | $25.95 Million | 20.74% | 2.63x | $66.18K |
| Biotest Aktiengesellschaft (BIO) | $380.40 Million | -16.67% | 1.90x | $976.15 Million |
| Biotest Aktiengesellschaft (BIO3) | $476.90 Million | -0.99% | 1.32x | $656.94 Million |
About SPOBAG AG
Leo International Precision Health AG engages in the healthcare technology business in Germany. The company is based in Garching bei München, Germany.